Nucleolar p14ARF overexpression in Reed-Sternberg cells in Hodgkin's lymphoma -: Absence of p14ARF/Hdm2 complexes is associated with expression of alternatively spliced Hdm2 transcripts

被引:19
作者
García, JF
Villuendas, R
Sánchez-Beato, M
Sánchez-Aguilera, A
Sánchez, L
Prieto, I
Piris, MA
机构
[1] Ctr Nacl Invest Oncol, Mol Pathol Program, Madrid 28029, Spain
[2] Pharmacia Corp, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Madrid, Spain
关键词
D O I
10.1016/S0002-9440(10)64876-6
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The development of human cancers is frequently associated with the silencing of the two major tumor suppressor pathways represented by retinoblastoma. protein and p53. As the incidence of p53 mutations is significantly lower in Hodgkin's lymphoma than in other neoplasias, we investigated whether the malfunction of other proteins in this pathway could be responsible for its inactivation. Because the existence of nucleolar complexes between p14(ARF) and Hdm2 has been described as having a critical effect on p53 function by inhibiting its degradation, we analyzed the expression and subcellular localization of these proteins in 52 cases and in Hodgkin's cell lines. Two of four cell lines revealed loss of p14(ARF) expression secondary to gene promoter methylation, this being mutually exclusive with p53 mutations (1 of 4), illustrating the existence of selective pressure to inactivate the p53 pathway. The majority of Hodgkin's samples showed a strong nucleolar expression of p14(ARF) that was not associated with Hdm2. They also showed the existence of Hdm2/p53 complexes, and the absence of complexes containing either p14(ARF)/Hdm2 or p14(ARF)/p53. The different localization of Hdm2 (nucleoplasm) and p14(ARF) (nucleoli) observed in Hodgkin's tumors and cell lines is associated with the presence of short alternatively spliced transcripts of Hdm2 lacking the ARF-binding region and the nuclear export signal. The absence of these p14(ARF)/Hdm2 nucleolar complexes could be sufficient to inactivate the pathway and may explain the low frequency of p53 mutations in this tumor.
引用
收藏
页码:569 / 578
页数:10
相关论文
共 51 条
  • [21] Matsumoto R, 1998, CANCER RES, V58, P609
  • [22] MDM2 - master regulator of the p53 tumor suppressor protein
    Momand, J
    Wu, HH
    Dasgupta, G
    [J]. GENE, 2000, 242 (1-2) : 15 - 29
  • [23] THE MDM-2 ONCOGENE PRODUCT FORMS A COMPLEX WITH THE P53 PROTEIN AND INHIBITS P53-MEDIATED TRANSACTIVATION
    MOMAND, J
    ZAMBETTI, GP
    OLSON, DC
    GEORGE, D
    LEVINE, AJ
    [J]. CELL, 1992, 69 (07) : 1237 - 1245
  • [24] Mutation of the p53 gene is not a typical feature of Hodgkin and Reed-Sternberg cells in Hodgkin's disease
    Montesinos-Rongen, M
    Roers, A
    Küppers, R
    Rajewsky, K
    Hansmann, ML
    [J]. BLOOD, 1999, 94 (05) : 1755 - 1760
  • [25] A long twentieth century of the cell cycle and beyond
    Nurse, P
    [J]. CELL, 2000, 100 (01) : 71 - 78
  • [26] ONCOPROTEIN MDM2 CONCEALS THE ACTIVATION DOMAIN OF TUMOR SUPPRESSOR-P53
    OLINER, JD
    PIETENPOL, JA
    THIAGALINGAM, S
    GVURIS, J
    KINZLER, KW
    VOGELSTEIN, B
    [J]. NATURE, 1993, 362 (6423) : 857 - 860
  • [27] INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene
    Pinyol, M
    Hernández, L
    Martínez, A
    Cobo, F
    Hernández, S
    Beà, S
    López-Guillermo, A
    Nayach, I
    Palacín, A
    Nadal, A
    Fernández, PL
    Montserrat, E
    Cardesa, A
    Campo, E
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (06) : 1987 - 1996
  • [28] The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53
    Pomerantz, J
    Schreiber-Agus, N
    Liegeois, NJ
    Silverman, A
    Alland, L
    Chin, L
    Potes, J
    Chen, K
    Orlow, I
    Lee, HW
    Cordon-Cardo, C
    DePinho, RA
    [J]. CELL, 1998, 92 (06) : 713 - 723
  • [29] Signaling to p53: Breaking the MDM2-p53 circuit
    Prives, C
    [J]. CELL, 1998, 95 (01) : 5 - 8
  • [30] QUELLE DE, 1995, CELL, V83, P993